Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000632368 | SCV000753546 | likely benign | Neurofibromatosis, type 1 | 2024-12-16 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002438658 | SCV001189314 | uncertain significance | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2024-06-28 | criteria provided, single submitter | clinical testing | The p.T2609S variant (also known as c.7826C>G), located in coding exon 53 of the NF1 gene, results from a C to G substitution at nucleotide position 7826. The threonine at codon 2609 is replaced by serine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Genome- |
RCV000632368 | SCV002561154 | uncertain significance | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002499044 | SCV002815548 | uncertain significance | Neurofibromatosis, familial spinal; Juvenile myelomonocytic leukemia; Neurofibromatosis, type 1; Neurofibromatosis-Noonan syndrome; Café-au-lait macules with pulmonary stenosis | 2022-05-05 | criteria provided, single submitter | clinical testing | |
Gene |
RCV003313115 | SCV004012601 | uncertain significance | not provided | 2024-03-26 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 25486365) |